5-Aryl thiazolidine-2,4-diones as selective PPARgamma agonists

  • Bioorg Med Chem Lett. 2003 May 19;13(10):1801-4. doi: 10.1016/s0960-894x(03)00257-9.
Hiroo Koyama  1 ,  Julia K Boueres ,  Wei Han ,  Edward J Metzger ,  Jeffrey P Bergman ,  Dominick F Gratale ,  Daniel J Miller ,  Richard L Tolman ,  Karen L MacNaul ,  Joel P Berger ,  Thomas W Doebber ,  Kwan Leung ,  David E Moller ,  James V Heck ,  Soumya P Sahoo
Affiliations
  • 1. Department of Medicinal Chemistry, Merck Research Laboratories, PO Box 2000, Rahway, NJ 07065-0900, USA. [email protected]
PMID: 12729668 DOI: 10.1016/s0960-894x(03)00257-9
Abstract

A series of 5-aryl thiazolidine-2,4-diones containing 4-phenoxyphenyl side chains was designed, synthesized, and evaluated for PPAR Agonist activities. One such compound 28 exhibited comparable levels of glucose correction to rosiglitazone in the db/db mouse type 2 diabetes animal model.